{"id":"administration-of-quetiapine-xr","safety":{"commonSideEffects":[{"rate":"18-27%","effect":"Somnolence/sedation"},{"rate":"9-16%","effect":"Dry mouth"},{"rate":"9-14%","effect":"Dizziness"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"13-19%","effect":"Headache"},{"rate":"8-11%","effect":"Constipation"},{"rate":"2-6%","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL3188993","moleculeType":"Small molecule","molecularWeight":"883.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine blocks dopamine and serotonin receptors, reducing abnormal neurotransmitter activity associated with psychotic symptoms and mood disturbances. The extended-release (XR) formulation provides sustained drug delivery over 24 hours, improving medication adherence and maintaining steady-state plasma concentrations.","oneSentence":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:56.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Bipolar depression"},{"name":"Adjunctive treatment of major depressive disorder"}]},"trialDetails":[{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT04338321","phase":"PHASE3","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2020-08-21","conditions":"Depressive Disorder, Major","enrollment":676},{"nctId":"NCT04936126","phase":"PHASE4","title":"Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-07","conditions":"Treatment Resistant Depression","enrollment":150},{"nctId":"NCT01342380","phase":"","title":"Pioglitazone and Quetiapine XR Pharmacogenetic Study","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-02","conditions":"Bipolar Disorder, Major Depressive Disorder","enrollment":42},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT02901587","phase":"PHASE1","title":"Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":119},{"nctId":"NCT00498628","phase":"PHASE2","title":"Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2007-12","conditions":"Alcoholism, Alcohol Abuse","enrollment":224},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT01165541","phase":"PHASE2","title":"A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-09","conditions":"Alcohol Dependence","enrollment":20},{"nctId":"NCT01971203","phase":"NA","title":"Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2009-09","conditions":"Major Depressive Disorder, Generalized Anxiety Disorder","enrollment":62},{"nctId":"NCT01594996","phase":"","title":"European Drug Utilization Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04-24","conditions":"Major Depressive Disorder (MDD)","enrollment":814},{"nctId":"NCT03317236","phase":"PHASE4","title":"Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2017-03-13","conditions":"Healthy","enrollment":24},{"nctId":"NCT00955474","phase":"PHASE4","title":"Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder With Psychotic Features","enrollment":32},{"nctId":"NCT00880919","phase":"PHASE3","title":"Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2008-06","conditions":"Borderline Personality Disorder","enrollment":95},{"nctId":"NCT00671853","phase":"PHASE3","title":"Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-04","conditions":"Bipolar Disorder, Anxiety, Anxiety Disorders","enrollment":120},{"nctId":"NCT00868374","phase":"PHASE3","title":"Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder","status":"TERMINATED","sponsor":"Keming Gao","startDate":"2008-06","conditions":"Major Depressive Disorder, Generalized Anxiety Disorder","enrollment":23},{"nctId":"NCT00951483","phase":"PHASE4","title":"Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients","status":"COMPLETED","sponsor":"Loyola University","startDate":"2009-07","conditions":"Depression, Anxiety","enrollment":91},{"nctId":"NCT00982345","phase":"PHASE4","title":"Brain Imaging of Quetiapine Response in Anxious Depression","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2009-03","conditions":"Major Depression","enrollment":20},{"nctId":"NCT01256177","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"Bipolar Depression","enrollment":361},{"nctId":"NCT00619892","phase":"PHASE4","title":"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2008-02","conditions":"Panic Disorder","enrollment":26},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT00253266","phase":"PHASE4","title":"Venlafaxine Augmentation in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Max-Planck-Institute of Psychiatry","startDate":"2008-04","conditions":"Depression","enrollment":126},{"nctId":"NCT01244711","phase":"PHASE4","title":"Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-09","conditions":"Major Depression, Generalized Anxiety Disorder","enrollment":1},{"nctId":"NCT00766350","phase":"PHASE4","title":"Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2008-11","conditions":"Fibromyalgia","enrollment":90},{"nctId":"NCT00606541","phase":"EARLY_PHASE1","title":"An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-01","conditions":"Social Anxiety Disorder","enrollment":55},{"nctId":"NCT00811473","phase":"PHASE3","title":"Pediatric Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Bipolar Depression","enrollment":193},{"nctId":"NCT02142556","phase":"PHASE3","title":"The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2008-11","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT02132286","phase":"PHASE4","title":"Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-12","conditions":"Major Depressive Disorder","enrollment":57},{"nctId":"NCT00631748","phase":"NA","title":"Quetiapine for the Reduction of Cocaine Use","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-02","conditions":"Cocaine Dependence, Cocaine Abuse, Cocaine Addiction","enrollment":60},{"nctId":"NCT01363310","phase":"PHASE3","title":"The Quietude Study: Quetiapine Use for Agitated Depression","status":"TERMINATED","sponsor":"Physicians Research And Education Network","startDate":"2010-10","conditions":"Depression With Prominent Agitation","enrollment":250},{"nctId":"NCT01200901","phase":"PHASE4","title":"Quetiapine in Melancholic Depression","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-09","conditions":"Depression, Healthy","enrollment":20},{"nctId":"NCT00954122","phase":"PHASE4","title":"Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT01197846","phase":"PHASE3","title":"Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder","status":"COMPLETED","sponsor":"Centro de Investigación Biomédica en Red de Salud Mental","startDate":"2010-09","conditions":"Bipolar Disorder","enrollment":28},{"nctId":"NCT00681629","phase":"PHASE4","title":"Schizophrenic Patients in Integrated Care","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":7},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00883493","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Acute Bipolar Depression","enrollment":421},{"nctId":"NCT00640562","phase":"PHASE3","title":"Quetiapine Extended Release Depression Symptoms","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Schizophrenia, Depression","enrollment":216},{"nctId":"NCT00789854","phase":"PHASE3","title":"Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":688},{"nctId":"NCT00882518","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT00931723","phase":"PHASE4","title":"Adult Bipolar Mania","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Acute Mania","enrollment":356},{"nctId":"NCT00857584","phase":"PHASE3","title":"Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Bipolar Disorder, Bipolar Depression","enrollment":27},{"nctId":"NCT01128114","phase":"PHASE4","title":"Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Acute Bipolar Mania","enrollment":32},{"nctId":"NCT00389064","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Anxiety Disorders","enrollment":450},{"nctId":"NCT01527448","phase":"NA","title":"Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II","status":"COMPLETED","sponsor":"BC Women's Hospital & Health Centre","startDate":"2008-04","conditions":"Postpartum Depression","enrollment":26},{"nctId":"NCT00723970","phase":"PHASE4","title":"Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression","status":"COMPLETED","sponsor":"McMaster University","startDate":"2007-06","conditions":"Major Depressive Disorder, Insomnia, Hot Flashes","enrollment":40},{"nctId":"NCT00779506","phase":"PHASE4","title":"Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Schizophrenia","enrollment":96},{"nctId":"NCT01202617","phase":"","title":"Seroquel XR in the Long Term Treatment of Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Relapse in Schizophrenia","enrollment":1606},{"nctId":"NCT00983320","phase":"PHASE4","title":"Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2008-04","conditions":"Fibromyalgia","enrollment":52},{"nctId":"NCT00934726","phase":"","title":"Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Quality of Life in Schizophrenia","enrollment":150},{"nctId":"NCT01250847","phase":"PHASE4","title":"Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)","status":"UNKNOWN","sponsor":"Severance Hospital","startDate":"2010-11","conditions":"Abnormal Mental State, Schizophrenia","enrollment":83},{"nctId":"NCT00892463","phase":"PHASE4","title":"Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2009-05","conditions":"Depressive Disorder, Major","enrollment":26},{"nctId":"NCT00675896","phase":"PHASE4","title":"A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Dr Alexander McIntyre Inc.","startDate":"2007-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT00534599","phase":"PHASE3","title":"Generalized Anxiety Disorder Adjunct Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-08","conditions":"Anxiety, Anxiety Disorders, Anxiety Neuroses","enrollment":409},{"nctId":"NCT00872716","phase":"PHASE2","title":"Quetiapine in Specific Phobia","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2009-04","conditions":"Specific Phobia","enrollment":60},{"nctId":"NCT01239589","phase":"","title":"European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Acute Bipolar Manic Episode","enrollment":1280},{"nctId":"NCT01212575","phase":"","title":"A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Schizophrenia","enrollment":186},{"nctId":"NCT00879307","phase":"PHASE3","title":"Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2009-03","conditions":"BIPOLAR DISORDER","enrollment":100},{"nctId":"NCT00965536","phase":"","title":"Nis Register Study Comparing Seroquel and Seroquel Prolong","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Comparing Hospitalisation Time With Seroquel and Seroquel Prolong","enrollment":200},{"nctId":"NCT01214135","phase":"","title":"A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT00758251","phase":"","title":"Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01029145","phase":"","title":"Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-12","conditions":"Bipolar Disorder, New Occurred Episode","enrollment":537},{"nctId":"NCT00986167","phase":"PHASE4","title":"Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry","status":"UNKNOWN","sponsor":"Bayside Health","startDate":"2009-10","conditions":"Schizophrenia, Psychosis","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":119,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Administration of quetiapine XR","genericName":"Administration of quetiapine XR","companyName":"Tri-Service General Hospital","companyId":"tri-service-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Bipolar depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}